Komori
Rohto Pharmaceutical (4527) · RiskReframed

Litigation risks, including intellectual property infringement and product liability

First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026.

21entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2024-Q32016: 120162017: 320172018: 320182019: 320192020: 320202021: 220212022: 220222023: 220232024: 120242025: 020252026: 12026
Same theme, other companies

Rohto Pharmaceutical moved to the "Worse" side of this theme in 2026, 2 years after the typical company in this theme (2024).

The whole theme swung hardest in 2024: 5 of 15 companies on the "Worse" side.

2 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 57 companies compared. The sentences above are computed from all 57.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「In addition, if the intellectual property rights of the Group are not adequately protected, or if the Group is determined to have infringed a third party's intellectual property rights, this could result in a decline in competitiveness, claims for damages and payments of consideration. Furthermore, depending on the substance and outcome of litigation relating to product liability, environmental matters, transactions, labor and other issues, operating results and financial condition could be affected.」

    The Company has reorganized these as a group of risks covering intellectual property, product liability and environmental matters, as well as misconduct relating to transactions, labor and compliance and human rights violations.
  2. FY2024-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  3. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  4. FY2024-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  5. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  6. FY2023-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  7. FY2022-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  8. FY2021-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  9. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  10. FY2021-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  11. FY2020-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  12. FY2020-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  13. FY2020-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  14. FY2019-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  15. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  16. FY2019-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  17. FY2018-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  18. FY2018-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  19. FY2018-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes to the risks of litigation relating to intellectual property infringement, product liability and other matters.
  20. FY2017RestatedAnnual report

    「If the Group is unable to adequately protect its intellectual property, third parties may use the Group's technologies or other assets, adversely affecting its competitiveness in the market. The Group takes care and conducts investigations to avoid infringing the intellectual property rights of third parties. However, if the Group were to infringe a third party's intellectual property rights, it could face claims for damages and other litigation, or incur payments of consideration, which could affect business performance and financial condition.」

    The Company has reconfirmed the risks relating to the protection and infringement of intellectual property rights, product liability and environmental litigation.
  21. FY2016First statedAnnual report

    「In addition to intellectual property rights, the Group may face litigation relating to product liability, environmental matters and other issues, and the substance and outcome of such litigation could affect business performance and financial condition.」

    In addition to intellectual property rights, the Company identifies the possibility of litigation relating to product liability and environmental matters, as well as the potential impact of the substance and outcome of such litigation.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.